How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,795 results for

Bacterial Vaginosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Bacterial vaginosis in pregnancy and risk of spontaneous preterm delivery

Bacterial vaginosis in pregnancy and risk of spontaneous preterm delivery Bacterial vaginosis, proposal for the Danish guideline meeting 2015 (version 190214) Page 1 Bacterial vaginosis in pregnancy and risk of spontaneous preterm delivery Approved at the obstetrical guideline-meeting January 2015 Danish Society of Obstetrics and Gynecology (DSOG) Update February 2019 The Lancet has now published reference 31b, by Subtil et al. (2018). The 2015 version of the DSOG guideline included (...) The objective of this guideline is to evaluate bacterial vaginosis in pregnancy concerning • Different treatments for prevention of preterm delivery. • Screening of pregnant women with low as well as high risk of sPTD. • Stratification into gestational ages below and above 16 weeks. • Diagnostic methods. Key words Bacterial vaginosis, vaginal pH, pH-glove, vaginal discharge, Nugent score, Amsel score, Gardnerella vaginalis, Mobiluncus species, preterm delivery, preterm birth, GRADE, clindamycin

2019 Nordic Federation of Societies of Obstetrics and Gynecology

3. IL-36γ is elevated in cervicovaginal epithelial cells in women with bacterial vaginosis and in vitro after infection with microbes associated with bacterial vaginosis. (PubMed)

IL-36γ is elevated in cervicovaginal epithelial cells in women with bacterial vaginosis and in vitro after infection with microbes associated with bacterial vaginosis. Recently, the IL-36 cytokines were shown to be elevated in women with non-Lactobacillus-dominated vaginal microbiomes. Here, we evaluated IL36G expression in clinical samples from women with and without bacterial vaginosis (BV) and a human 3-D cervical epithelial cell model. IL36G expression was significantly elevated (...) in cervicovaginal epithelial cells isolated from BV-positive women and corresponded with increased neutrophil counts relative to BV-negative women. Additionally, specific BV-associated bacterial species as well as a polymicrobial cocktail significantly induced IL36G expression in vitro. These findings suggest that IL-36γ may exhibit an important function in the host response to BV and other sexually transmitted infections.© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases

2019 Journal of Infectious Diseases

4. Screening and Management of Bacterial Vaginosis in Pregnancy

Screening and Management of Bacterial Vaginosis in Pregnancy No. 211-Screening and Management of Bacterial Vaginosis in Pregnancy - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 39, Issue 8, Pages e184–e191 No. 211-Screening and Management of Bacterial Vaginosis in Pregnancy x Mark H. Yudin Correspondence Corresponding Author: Dr. Mark Yudin, Department of Obstetrics and Gynecology, University of Toronto, Toronto (...) , ON. , MD ∗ , x Mark H. Yudin Correspondence Corresponding Author: Dr. Mark Yudin, Department of Obstetrics and Gynecology, University of Toronto, Toronto, ON. x Deborah M. Money , MD No. 211, August 2017 DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective To review the evidence and provide recommendations on screening for and management of bacterial vaginosis in pregnancy. Options The clinical practice options considered

2017 Society of Obstetricians and Gynaecologists of Canada

5. Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. (PubMed)

Efficacy and safety of vaginally administered lyophilized Lactobacillus crispatus IP 174178 in the prevention of bacterial vaginosis recurrence. Bacterial vaginosis (BV) is a recurrent disease in women despite treatment by antibiotics. This study investigated the impact of a vaginal probiotic, Lactobacillus crispatus IP174178* (Lc), on the rate of recurrence and time to recurrence.A prospective, multi-centre, double blind, randomised phase III trial in women with at least two documented

Full Text available with Trip Pro

2018 Journal of gynecology obstetrics and human reproduction

6. Detection of ureaplasmas and bacterial vaginosis associated bacteria and their association with non-gonococcal urethritis in men. (PubMed)

Detection of ureaplasmas and bacterial vaginosis associated bacteria and their association with non-gonococcal urethritis in men. No aetiology is found in up to 40% of men with symptomatic urethritis. Male partners of women with bacterial vaginosis (BV) may be at higher risk of non-gonococcal urethritis (NGU). The aim of this study was to examine the role of BV associated bacteria in first-void urine (FVU) in 97 asymptomatic men without urethritis (controls) and 44 men (cases) with NGU

Full Text available with Trip Pro

2019 PLoS ONE

7. A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis

A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis A novel single oral dose granule formulation of secnidazole 2 g, a 5-nitroimidazole with a longer half-life (∼17 hours) than metronidazole (∼8 hours), is being developed to treat bacterial vaginosis.We sought to evaluate the effectiveness and safety of single-dose secnidazole 2 g compared to placebo for the treatment (...) of women with bacterial vaginosis.In all, 189 women with bacterial vaginosis were randomized 2:1 to receive a single oral dose of secnidazole 2 g (N = 125) or matched placebo (N = 64) at 21 centers in the United States. The primary endpoint was the proportion of clinical outcome responders, defined as those with: (1) normal vaginal discharge; (2) negative 10% potassium hydroxide whiff test; and (3) <20% clue cells of total epithelial cell count on microscopic examination of the vaginal wet mount, using

2018 EvidenceUpdates

8. Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. (PubMed)

Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial. Preterm delivery during pregnancy (<37 weeks' gestation) is a leading cause of perinatal mortality and morbidity. Treating bacterial vaginosis during pregnancy can reduce poor outcomes, such as preterm birth. We aimed to investigate whether treatment of bacterial vaginosis decreases late miscarriages or spontaneous very preterm birth.PREMEVA was a double-blind randomised (...) controlled trial done in 40 French centres. Women aged 18 years or older with bacterial vaginosis and low-risk pregnancy were eligible for inclusion and were randomly assigned (2:1) to three parallel groups: single-course or triple-course 300 mg clindamycin twice-daily for 4 days, or placebo. Women with high-risk pregnancy outcomes were eligible for inclusion in a high-risk subtrial and were randomly assigned (1:1) to either single-course or triple-course clindamycin. The primary outcome was a composite

2018 Lancet

9. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis

Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 3, Pages 266–274 Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis (...) , x Kellie Murphy , MD x Kellie Murphy , x Gina Ogilvie , MD x Gina Ogilvie , x Caroline Paquet , RM x Caroline Paquet , x Julie van Schalkwyk , MD x Julie van Schalkwyk DOI: To view the full text, please login as a subscribed user or . Click to view the full text on ScienceDirect. Abstract Objective To review the evidence and provide recommendations on screening for and management of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis. Outcomes Outcomes evaluated include

2015 Society of Obstetricians and Gynaecologists of Canada

10. Secnidazole for treatment of bacterial vaginosis: a systematic review

Secnidazole for treatment of bacterial vaginosis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

11. Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis

Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis - Journal of Obstetrics and Gynaecology Canada Email/Username: Password: Remember me Search Terms Search within Search Volume 37, Issue 3, Pages 266–274 Vulvovaginitis: Screening for and Management of Trichomoniasis, Vulvovaginal Candidiasis, and Bacterial Vaginosis (...) , x Kellie Murphy , MD x Kellie Murphy , x Gina Ogilvie , MD x Gina Ogilvie , x Caroline Paquet , RM x Caroline Paquet , x Julie van Schalkwyk , MD x Julie van Schalkwyk DOI: Abstract Objective To review the evidence and provide recommendations on screening for and management of vulvovaginal candidiasis, trichomoniasis, and bacterial vaginosis. Outcomes Outcomes evaluated include the efficacy of antibiotic treatment, cure rates for simple and complicated infections, and the implications

2015 Society of Obstetricians and Gynaecologists of Canada

12. ‘Helcococcus massiliensis’ sp. nov., a new bacterial species isolated from the vaginal sample of a woman with bacterial vaginosis living in Dielmo, Senegal (PubMed)

‘Helcococcus massiliensis’ sp. nov., a new bacterial species isolated from the vaginal sample of a woman with bacterial vaginosis living in Dielmo, Senegal We report here the isolation of a new bacterial species 'Helcococcus massiliensis' strain Marseille P4590 (CSURP4590), isolated from the vaginal sample of a woman with bacterial vaginosis.

Full Text available with Trip Pro

2018 New Microbes and New Infections

13. Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis. (PubMed)

Gardnerella vaginalis and Prevotella bivia Trigger Distinct and Overlapping Phenotypes in a Mouse Model of Bacterial Vaginosis. Bacterial vaginosis (BV) is a common imbalance of the vaginal microbiota characterized by overgrowth of diverse Actinobacteria, Firmicutes, and Gram-negative anaerobes. Women with BV are at increased risk of secondary reproductive tract infections and adverse pregnancy outcomes. However, which specific bacteria cause clinical features of BV is unclear.We previously

Full Text available with Trip Pro

2019 Journal of Infectious Diseases

14. Association between obesity and bacterial vaginosis as assessed by Nugent score. (PubMed)

Association between obesity and bacterial vaginosis as assessed by Nugent score. Bacterial vaginosis is 1 of the most common vaginal conditions in the United States. Recent studies have suggested that obese women have an abnormal microbiota reminiscent of bacterial vaginosis; however, few studies have investigated the prevalence of bacterial vaginosis in overweight and obese populations. Moreover, despite the increased prevalence of obesity and bacterial vaginosis in black women (...) , it is not known whether racial disparities exist in the relationship between obesity and bacterial vaginosis.The objective of this study was to examine the relationship between body mass index and bacterial vaginosis as determined by Nugent score and to determine the influence of race in this context.We performed a cross-sectional study using patient data and vaginal smears from 5918 participants of the Contraceptive CHOICE Project. Gram-stained vaginal smears were scored with the Nugent method

2019 American Journal of Obstetrics and Gynecology

15. Differential sexual network connectivity offers a parsimonious explanation for population-level variations in the prevalence of bacterial vaginosis: a data-driven, model-supported hypothesis. (PubMed)

Differential sexual network connectivity offers a parsimonious explanation for population-level variations in the prevalence of bacterial vaginosis: a data-driven, model-supported hypothesis. The prevalence of bacterial vaginosis (BV) and vaginal microbiota types varies dramatically between different populations around the world. Understanding what underpins these differences is important, as high-diversity microbiotas associated with BV are implicated in adverse pregnancy outcomes and enhanced

Full Text available with Trip Pro

2019 BMC Women's Health

16. The effect of prebiotic vaginal gel with adjuvant oral metronidazole tablets on treatment and recurrence of bacterial vaginosis: a triple-blind randomized controlled study. (PubMed)

The effect of prebiotic vaginal gel with adjuvant oral metronidazole tablets on treatment and recurrence of bacterial vaginosis: a triple-blind randomized controlled study. Bacterial vaginosis is a change in the normal vaginal bacterial flora that leads to loss of hydrogen peroxide producing lactobacilli and overgrowth of predominantly anaerobic bacteria. The present study was conducted to compare the effects of prebiotic vaginal gel with oral metronidazole tablet and metronidazole tablet alone (...) on treatment and recurrence of bacterial vaginosis.The present triple-blind randomized clinical trial was conducted in Sadatmandi Hospital in Robat-Karim town, where 100 patients were randomly divided into intervention (receiving a 5 mg prebiotic vaginal gel applicator plus three 250 mg metronidazole tablets per day for 7 days) and control (receiving a 5 mg placebo vaginal gel applicator and three 250 mg metronidazole tablets per day for 7 days) groups. Then, patients were assessed for bacterial vaginosis

2019 Archives of gynecology and obstetrics

17. Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial

Secnidazole Treatment of Bacterial Vaginosis: A Randomized Controlled Trial To evaluate secnidazole as a single oral dose treatment for bacterial vaginosis in a phase 2 randomized, double-blind, placebo-controlled study.In a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study, women with bacterial vaginosis who met all Amsel criteria (discharge; pH 4.7 or greater; 20% or greater clue cells; positive whiff test) were randomized one to one to one at 24 U.S. centers to 1 or 2 (...) (median age 33 years; 32% with four or more bacterial vaginosis episodes in the previous year; 54% black) with baseline Nugent scores 4 or greater. Clinical, microbiologic, and therapeutic cure rates were 67.7%, 40.3%, and 40.3% for 2 g secnidazole and 51.6%, 23.4%, and 21.9% for 1 g secnidazole compared with 17.7%, 6.5%, and 6.5% for placebo, respectively (P<.05 for secnidazole compared with placebo; all endpoints). Both doses were well-tolerated.Oral granules containing 1 and 2 g secnidazole were

2017 EvidenceUpdates

18. Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. (PubMed)

Evidence-based mixture containing Lactobacillus strains and lactoferrin to prevent recurrent bacterial vaginosis: a double blind, placebo controlled, randomised clinical trial. Bacterial vaginosis (BV) is the most common cause of vaginal discomfort in women. It is characterised by abnormal vaginal microbiota with a depletion of lactobacilli and predominance of anaerobic microorganisms, mainly Gardnerella vaginalis and Atopobium vaginae. Although antibiotics represent an effective therapeutic

2019 Beneficial microbes

19. Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: A randomised, open-label longitudinal study in Rwandan women. (PubMed)

Contraceptive rings promote vaginal lactobacilli in a high bacterial vaginosis prevalence population: A randomised, open-label longitudinal study in Rwandan women. Hormonal contraception has been associated with a reduced risk of vaginal dysbiosis, which in turn has been associated with reduced prevalence of sexually transmitted infections (STIs), including HIV. Vaginal rings are used or developed as delivery systems for contraceptive hormones and antimicrobial drugs for STI and HIV prevention (...) vaginae, and fluorescent in situ hybridization to visualize cell-adherent bacteria. Ring biomass was measured by crystal violet staining.Bacterial vaginosis (BV) prevalence was 48% at baseline. The mean Nugent score decreased significantly with ring use. The presence and mean log10 concentrations of Lactobacillus species in vaginal secretions increased significantly whereas those of G. vaginalis and presence of A. vaginae decreased significantly. Biomass accumulated on the CVRs with a species

Full Text available with Trip Pro

2018 PLoS ONE

20. Does bacterial vaginosis modify the effect of hormonal contraception on HIV seroconversion. (PubMed)

Does bacterial vaginosis modify the effect of hormonal contraception on HIV seroconversion. A recent study of HIV serodiscordant couples found that depot medroxyprogesterone acetate (DMPA) and oral contraceptive pills (OCPs) were associated with increased HIV risk in the presence, but not in the absence, of bacterial vaginosis. We assessed whether bacterial vaginosis is an effect modifier of the association between hormonal contraception and HIV seroconversion in female sex workers (FSWs (...) , 95% confidence interval (CI) 1.08-2.25; P = 0.02] and without (aHR 2.08, 95% CI 1.46-2.97; P < 0.001) bacterial vaginosis (interaction P = 0.4). Similarly, OCP use was associated with increased HIV risk both in the presence (aHR 1.50, 95% CI 0.94-2.39; P = 0.09) and absence (aHR 1.61, 95% CI 0.99-2.64; P = 0.06) of bacterial vaginosis (interaction P = 0.9), though neither stratum reached statistical significance. Implants were not associated with HIV seroconversion overall (aHR 0.99, 95% CI 0.40

2019 AIDS

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>